Reduced Mortality, Cytopenias, and Cardiovascular Events With Asciminib Compared With Ponatinib in Previously Treated Chronic Myeloid Leukemia: A Propensity-Matched Real-World Analysis (SOHO 2026) - Sep 1, 2026 - Abstract #CML-1365; Location: LEVEL 3, HALL B3; "In this large propensity-matched real-world study, asciminib was associated with significantly lower mortality, hematologic toxicity, thromboembolic complications, and cardiovascular events compared with ponatinib in previously treated CML. These findings support asciminib as a potentially safer therapeutic strategy for patients requiring later-line therapy."
Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR
|